JPRN-UMIN000000637已完成未知
Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer. - Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.
Juntendo University, School of Medicine0 个研究点目标入组 20 人开始时间: 2007年3月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who have: previous history of hypersensitivity to Gefitinib, uncontrolled infections, active autoimmune diseases, and serious cardiac disease; who have received continuous systemic steroids; who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co-investigator judged to be inappropriate to participate in this study.
研究者
相似试验
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
尚未招募
3 期
A study to compare Gefitinib tablet with Gefitinib and Chemotherapy inEGFR Mutation Positive Lung cancer patientsCTRI/2022/08/044570Tata Memorial Centre
已完成
不适用
Pharmacokinetic study of gefitinib in patients with non-small cell lung cancerAdvanced non-small cell lung cancerJPRN-UMIN000019412Shizuoka cancer center30
已完成
不适用
Analysis of Gefitinib(Drug) in lung cancer.CTRI/2017/05/008490Tata Memorial Hospital350
已完成
不适用
Phase I/II study of Gefitnib monotherapy as neo-adjuvant chemotherapy for cN2 lung adenocarcinoma with the EGFR mutatioJPRN-UMIN000004807KantoKoshinetsu lung cancer research group20